Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GALK1 | P51570 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27585332 | 0.76 | TSHR (0.45) | MAPTKDM4ETDP2NSD2POLB | |
| SCHEMBL30100799 | 0.76 | CA1 (0.38) | CA1CA2MAPTKDM4EKMT2A | |
| SCHEMBL17839691 | 0.76 | CA1 (0.38) | CA1CA2MAPTKDM4EKMT2A | |
| SCHEMBL5352485 | 0.74 | MAPT (0.41) | MAPTKDM4ETDP2NSD2POLB | |
| SCHEMBL29963467 | 0.73 | HRH4 (0.38) | CA1CA2MAPTKDM4ETDP2 | |
| SCHEMBL28560362 | 0.73 | HRH4 (0.38) | CA1CA2MAPTKDM4ETDP2 | |
| SCHEMBL14460001 | 0.72 | TSHR (0.35) | MAPTTDP1HTTTSHRDYRK1A | |
| SCHEMBL4136722 | 0.69 | CYP3A4 (0.43) | MAPTKDM4ETDP2NSD2POLB | |
| SCHEMBL2133978 | 0.69 | CYP2A6 (0.43) | CA1CA2MAPTKDM4ETDP2 | |
| SCHEMBL21530568 | 0.69 | MAPT (0.38) | MAPTKDM4ETDP2NSD2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656143-B1 | NOVEL USE OF QUINOLONE ANTIBIOTICS | BAYER ANIMAL HEALTH GMBH (DE) | 2011-10-12 | — | — | EP | claimed |
| US-20070082911-A1 | Novel use of quinolone antibiotics | ELANCO ANIMAL HEALTH GMBH (DE) | 2007-04-12 | — | — | US | claimed |
| US-8658645-B2 | Use of quinolone antibiotics | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-25 | — | — | US | disclosed |
| US-8278442-B2 | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders | PROSIDION LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-7569563-B2 | Substituted quinolones II | AICURIS GMBH & CO. HK (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20080261964-A1 | Substituted quinolones II | AICURIS GMBH & CO. KG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| US-20070082911-A1 | Novel use of quinolone antibiotics | ELANCO ANIMAL HEALTH GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| EP-1140850-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6248739-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | disclosed |
| WO-2000040561-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | OPRM1, OPRK1, OPRD1 | CA1 4871/4885CA2 4563/4885MAPT 2993/4885 |
| US-20080261964-A1 | Substituted quinolones II | TOP2A, TPMT, TOP2B | CA1 3802/4885CA2 2524/4885MAPT 2639/4885 |
| US-20070082911-A1 | Novel use of quinolone antibiotics | QARS1, NQO2, DHX35 | CA1 4739/4885CA2 3041/4885MAPT 4399/4885 |
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | CA1 4367/4885CA2 3342/4885MAPT 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.